NeuroSense Therapeutics Ltd. has unveiled a groundbreaking collaboration in Alzheimer’s Disease (AD) drug development with Genetika+, a pioneer in precision medicine for psychiatry and neurology. This strategic partnership is set to revolutionize the landscape of AD treatment by integrating Genetika+’s cutting-edge technology, which derives frontal cortex neurons from individual patients’ blood to quantify drug-induced neuronal plasticity in vitro, with NeuroSense’s innovative PrimeC therapy.
The collaboration will commence in NeuroSense’s ongoing Phase 2 AD clinical trial, leveraging Genetika+’s state-of-the-art technology to correlate clinical response with cellular effects. By utilizing Genetika+’s technology as a human AD disease model, the collaboration aims to enhance mechanistic drug insights, identify patient subsets, and facilitate precision medicine approaches in AD drug development. This approach addresses key challenges in AD drug development, promoting disease and drug mechanistic understanding while increasing the likelihood of successful outcomes.
NeuroSense’s PrimeC therapy distinguishes itself from conventional methods by adopting a multi-targeted strategy that concurrently addresses Aβ aggregation, TDP-43, and other key disease-related pathologies. This unique approach diversifies therapeutic targets and offers the potential for more potent treatment outcomes. With compelling pre-clinical and clinical data, PrimeC demonstrates a synergistic mode of action and a strong safety profile, positioning it as a promising candidate for AD treatment.
Daphna Laifenfeld, co-founder and CSO at Genetika+, expressed optimism about the partnership, anticipating the possibility of bringing efficacious therapies to patients sooner and moving towards personalized, targeted treatments that significantly improve patient outcomes.
NeuroSense’s Phase 2 randomized, prospective double-blind, placebo-controlled study, known as RoAD, is currently enrolling patients at the Stroke and Cognition Institute, Rambam Health Care Campus, Haifa, Israel. This study aims to evaluate the therapeutic potential of PrimeC in treating AD by administering PrimeC or placebo twice daily for 12 months to 20 patients with mild to moderate non-familial AD. Endpoints include clinical outcome measurements, AD-related biomarkers, and markers of target engagement, with results expected to illuminate the safety, efficacy, and biological activity of PrimeC in AD.